First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study
Korean J Helicobacter Up Gastrointest Res 2018;18(2):120-126
Published online June 10, 2018
© 2018 Korean College of Helicobacter and Upper Gastrointestinal Research.

Moon Won Lee1, Gwang Ha Kim1,2, Sung Yong Han1, Young Joo Park1, Hye Kyung Jeon1, Bong Eun Lee1, Geun Am Song1

Department of Internal Medicine, Pusan National University School of Medicine1, Biomedical Research Institute, Pusan National University Hospital2, Busan, Korea
Correspondence to: Gwang Ha Kim
Department of Internal Medicine, Pusan National University School of Medicine, and Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea
Tel: +82-51-240-7869, Fax: +82-51-244-8180, E-mail: doc0224@pusan.ac.kr
ORCID: https://orcid.org/0000-0001-9721-5734
Received October 23, 2017; Revised December 12, 2017; Accepted December 15, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background/Aims: The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70∼85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. 
Materials and Methods: Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy. 
Results: This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001). 
Conclusions: Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.
Keywords : Concomitant therapy; Disease eradication; Helicobacter pylori; Standard therapy


December 2018, 18 (4)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)

Author ORCID Information